Factors Determining the Need for Ultrafiltration in Cardiorenal Syndrome

Area of Science:

• Nephrology
• Cardiology
• Critical Care Medicine

Background:

• Cardiorenal syndrome (CRS) frequently presents with hypervolemia, necessitating effective fluid management strategies.
• Diuretic therapy is the first-line treatment for hypervolemia in CRS, but can be ineffective in a significant patient subset.
• Ultrafiltration (UF) serves as a rescue therapy for refractory hypervolemia in CRS patients.

Purpose of the Study:

• To identify clinical and laboratory factors predicting the need for ultrafiltration (UF) in patients with cardiorenal syndrome and hypervolemia.
• To analyze the characteristics of patients requiring UF compared to those managed with diuretics alone.

Main Methods:

• A cohort of 88 hospitalized patients with hypervolemia due to cardiorenal syndrome was retrospectively analyzed.
• Data included demographics, medical history, laboratory values, blood pressure, diuretic response, spot urine sodium, and outcomes (creatinine, rehospitalization, mortality).
• Statistical analysis identified predictors for UF requirement.

Main Results:

• Ultrafiltration was required in 23.90% of patients due to insufficient response to diuretics.
• Men (34.10%) had a higher UF requirement rate than women (13.64%).
• Patients needing UF presented with lower systolic blood pressure, higher initial creatinine, and elevated pro-B-type natriuretic peptide (pro-BNP) levels. Increased initial creatinine (OR 6.443) and decreased spot urine sodium (OR 1.037) significantly predicted UF need.

Conclusions:

• Male gender, elevated pro-BNP, low spot urine sodium, low systolic blood pressure, and high initial creatinine are potential predictors for UF requirement in hypervolemic CRS patients.
• These factors may aid in early identification of patients likely to benefit from UF.
• Further validation in larger cohorts is needed to develop a predictive risk score for UF.